ARTICLE | Deals
Lead compound targeting IL-13 and TSLP trails bispecific competitors; second program set to advance behind it
By Paul Bonanos, Director of Biopharma Intelligence
May 16, 2024 5:43 PM UTC
Updated on May 17, 2024 at 9:01 PM UTC


The $850 million takeout of Proteologix will give J&J a bispecific antibody for immunologic diseases that’s ready for the clinic and could compete with programs against the same targets from three other pharmas.
Johnson & Johnson (NYSE:JNJ) said PX128, an antibody targeting IL-13 and TSLP, is ready for Phase I testing to treat atopic dermatitis and asthma. The pharma will gain PX128 in its all-cash deal for Proteologix Inc., a privately held company based in Redwood City, Calif., that has disclosed very little in its history…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/652448/with-proteologix-takeout-j-j-adds-bispecifics-for-atopic-dermatitis-asthma